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Abstract 
Background: The transmembrane receptor family Roundabout (Robo) was described to have an essential role in the 
developing nervous system. Recent studies demonstrated that Robo3 shows an altered expression in rheumatoid 
arthritis as well as in melanoma.
Context and purpose of the study: Until today no detailed studies of the two Robo3 isoforms (Robo3A and 
Robo3B) and their roles in rheumatoid arthritis synovial fibroblasts, respectively malignant melanoma are available. To 
get a better understanding regarding the role of Robo3A and Robo3B in the molecular process of rheumatoid arthritis 
and melanoma the exact characterization of expression and regulation is object of this study.
Results: mRNA and protein expression of the transcriptional variants were analyzed by quantitative RT-PCR respec-
tively western blotting and revealed particularly enhanced expression of Robo3B in rheumatoid arthritis and mela-
noma. Promoter assays and inhibitor studies also disclosed that there is apparently a cell- and isoform-specific regula-
tion of the Robo3 expression. Finally, dissimilar mRNA stabilities of Robo3A and Robo3B are identified as decisive 
posttranscriptional gene expression control.
Conclusion: In summary, this study supported an isotype specific role of Robo3B in disease hinting to different func-
tional roles of each isoform.
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Background
The repellent factor family of Slit and their receptors 
Roundabout (Robo) were originally described to be 
involved in path-finding of commissural neurons [1]. In 
this context, Robo receptors act synergistically with other 
receptors and ligands to enable or prevent midline cross-
ing of neurons. The Robo/Slit system is involved in regu-
lating cell–cell and cell–matrix interactions of migrating 
cells during embryonic development, mediate cell adhe-
sion of fibroblasts and induce tumor angiogenesis [2, 3].
There are four human Robo transmembrane receptors: 
Robo1/DUTT1, Robo2, Robo3/Rig-1 and Robo4/Magic 
Roundabout [4]. All share an extracellular domain con-
sisting of immunoglobulin-like (Ig) and fibronectin type 
III motifs. The cytoplasmic domains vary between the 
Robo members [5, 6].
Recently, it became obvious that there are several splice 
variants of Robo receptors with distinct functions in 
defined developmental stages or tissues and that they are 
conserved between different species [7, 8]. The two Robo3 
isoforms, Robo3A and Robo3B described by Camurri 
et al. differ only by a few amino acids at the N-terminus 
[7]. The variant Robo3B lacks exon 1 of Robo3A and starts 
from an alternative transcription start site (TSS) in intron 
1 of the NCBI reference gene (Fig. 1a). The first 53 amino 
acids of Robo3A are not part of Robo3B. The Robo3B pro-
tein contains 33 amino acids, not found in the Robo3A 
Open Access
Cancer Cell International
*Correspondence:  anja.bosserhoff@fau.de 
†Anke Ruedel and Mandy Schott contributed equally to this work 
1 Institute of Biochemistry, Emil-Fischer-Zentrum, Friedrich-Alexander 
University of Erlangen-Nürnberg, Fahrstrasse 17, 91054 Erlangen, 
Germany
Full list of author information is available at the end of the article
Page 2 of 10Ruedel et al. Cancer Cell Int  (2016) 16:71 
isoform (ENSEMBL) (Fig. 1b). Whereas the longest vari-
ant of Robo3, Robo3A, is incapable to bind the ligand Slit, 
the shorter variant, Robo3B, is able to bind Slit [1, 7]. So 
far, the expression levels of the two Robo3 variants are 
not determined in different cell types and disease-related 
changes of expression are not addressed.
Previous studies of our group detected significantly 
increased Robo3 expression in rheumatoid arthritis syno-
vial fibroblasts (RASF) compared to SF and in melanoma 
cell lines compared to melanocytes (NHEM) [9, 10]. This 
finding hints to deregulation of Robo3B in disease, how-
ever, no details about the specific isoforms, Robo3A and 
Robo3B, exist.
To get a better understanding regarding the role of the 
two Robo3 isoforms, the expression in different cell types 
as well as in RASF and different melanoma cell lines were 
analyzed at first. Promoter assays, inhibitory studies and 
mRNA stability experiments were used to explain the 
results obtained from the different expression pattern of 
Robo3A and Robo3B.
Methods
Cell lines and tissue culture
Synovial tissue samples from patients with RA were 
obtained immediately after opening the knee joint cap-
sule as previously described [9, 11, 12]. RASF were cul-
tured in DMEM (Sigma-Aldrich, St. Louis, Missouri, 
USA) + 10 % fetal calf serum (PAN Biotech, Aidenbach, 
Germany) + penicillin/streptavidin (PAN Biotech). These 
cells were incubated under humid conditions in a 5  % 
CO2 incubator at 37 °C.
The human melanoma cell lines Mel Im, A375, Hmb2, 
HTZ19d, Mel Wei, Mel Ei were maintained in DMEM 
and Mel Juso in RPMI (Sigma-Aldrich) supplemented 
with 10  % FCS and P/S. The cells were cultured in an 













































































































Fig. 1 a Schematic structure of Robo3A and Robo3B. Robo3B lacks exon 1 of Robo3A and starts from an alternative transcription start site (TSS) in 
intron 1 of the NCBI reference gene, Robo3A [7]. The first 53 amino acids of Robo3A are not part of Robo3B. The Robo3B protein contains 33 amino 
acids, not being found in the Robo3A isoform (ENSEMBL). b Robo3B mRNA expression relative to Robo3A mRNA expression, determined via qRT-
PCR. The majority of normal tissues exhibit a higher Robo3B expression compared to Robo3A, except all tissues of the brain and a few others
Page 3 of 10Ruedel et al. Cancer Cell Int  (2016) 16:71 
Isolation of RNA, reverse transcription and quantitative 
real‑time PCR
Total cellular RNA was isolated from cultured cells using 
the Total RNA Kit (VWR, Darmstadt, Germany) and 
cDNAs were generated as described before [13]. Real-
time quantitative PCR (qRT-PCR) was performed using 
SYBR Green master mix (QIAGEN) with primer pairs for 
Robo3A (5′- GAACTTGTTCGCGGACTCTC -3′ and 
5′- CCCGTTCTTGTACCACTCA -3′), Robo3B (5′-CC 
CTCTGGAGCCTCAATCTC-3′ and 5′-CCCCGTTCT 
TGTACCACTCA -3′), β-actin (5′-CTACGTGGCCCTGG 
ACTTCGAGC-3′ and 5′-GATGGAGCCGCCGATCC 
ACACGG-3′) and MIA (5′-TTCAGGGTGACTACTAC 
GGTCGCCTGGCTGCTCGTCTGGG-3′ and 5′-CCCA 
GACGAGCAGCCAGGCGACCGTAGTAGTCACC 
CTGAA-3′). Relative gene expression was normalized to 
β-actin mRNA levels using the comparative cycle thresh-
old (Ct) method. Specificity of the Robo3 isoform prim-
ers was confirmed by sequencing of the PCR products, 
Robo3A and Robo3B.
Protein isolation and western blot analysis
Protein extracts from primary cells and cell lines were 
homogenized in 100 or 200 μl RIPA-buffer (50 mM Tris–
HCl pH 7.5; 150 mM NaCl; 1 % (w/v) Nonidet® P40; 0.5 % 
(w/v) Natriumdesoxycholat; 0.1  % (w/v) SDS; Protease 
inhibitors). Insoluble fragments were removed by centrif-
ugation at 13,000  rpm for 10 min. The supernatant was 
stored at −20  °C. For western blot, protein lysates were 
separated on 7.5  % SDS-PAGE gels and blotted onto a 
PVDF membrane [14]. After blocking with 5 % milk pow-
der/TBS-T (1 %), primary antibodies were applied (anti-
Robo3B, 1:500, BioGenes; anti-β-actin, 1:4000, Sigma). 
Alkaline phosphatase-conjugated anti-rabbit (1:4000, cell 
signaling) or anti-mouse antibody (1:3000, NEB) served 
as secondary antibodies.
Peptide‑antibody production
A specific antibody was generated against the amino 
acids 18-31 of Robo3B (QFPCLNALRHPLSP) in rabbits 
by BioGenes GmbH (Berlin).
Cloning of Robo3A and Robo3B promoter region
Human Robo3 from −500 to −1 bp relative to the trans-
lation start was amplified by PCR (Robo3A: 5′-GACGG 
TACCGGGCAGAAGG-3′ and 5′-GACAAGCTTCTGC 
AGCAGCGTTTTC-3′; Robo3B: 5′- CCCTTGAAATGA 
AGCGTGATTATCC-3′ and 5′-CTCCTATGCTTCTCT 
GCGGAGC -3′) using Taq®-Polymerase (Roche, Man-
nheim, Germany). Subsequently, the amplified frag-
ments were cloned into a pGL4basic vector (Promega 
Corporation, Madison, WI, USA) via HindIII-HF (NEB, 
Frankfurt am Main, Germany) and KpnI-HF (Robo3A) 
respectively EcoRV-HF (Robo3B) restriction sites. The 
vector sequences were confirmed by Sanger sequencing.
Reporter gene assays
The tumor cell lines (150,000–200,000 cells) were cul-
tured in six-well plates for 24  h and then treated with 
cationic lipid/plasmid DNA suspension: 1  µg of lucif-
erase reporter plasmid (Robo3A, Robo3B or an empty 
pGL4basic vector) and 0.1 µg of the internal control plas-
mid pRL-TK. Twenty-four hours after the transfection 
the cells were harvested and the lysate was analyzed for 
luciferase activity with a luminometer using Promega 
dual-luciferase assay reagent [14]. At least three inde-
pendent transfection experiments were performed for 
each construct.
Cell treatments
The melanoma cell line Mel Ei (150,000 cells) were cul-
tured in six-well plates and were treated for 24  h with 
different inhibitors (SB431542 InvivoGen 2  μM; S3I-
201 Sigma-Aldrich 20  mM; Dorsomorphin Tebi-bio 
2  mM; LY-294002 Sigma-Aldrich 20  mM; Wortman-
nin Sigma-Aldrich 10 mM; UO126 Calbiochem 10 mM; 
Vemurafenib Active Biochem 100  μM; KT5720 Merck 
Millipore 100  nM; Bisindolylmaleimide II Santa Cruz 
10 μM; Gö 6983 Santa Cruz 10 μM; Wnt Agonist Calbio-
chem 10 μM). For the stability assay the cells were treated 
with α-Amanitin (AppliChem, 5 mM). After isolation of 
total RNA, quantitative RT-PCR was performed to detect 
relative gene expression. Normalization was based on 
mRNA input in this experiment.
Statistical analysis
Calculations were performed using the GraphPad Prism 
software (GraphPad software, Inc., San Diego, USA). 
All results are indicated as mean ±  SEM and compari-
son between groups were made using the Student paired 
t test (*: p  <  0.05; **: p  <  0.01; ***: p  <  0.001; ns: not 
significant).
Results
Robo3 expression in normal tissues
It is already known that the receptor Robo3 is ubiqui-
tous expressed in all normal tissues (see proteinatlas.
org). However, no details concerning the expression of 
the two isoforms (Fig.  1a) are existent, as all previously 
used antibodies recognize both variants and primers 
used in RT-PCR by most studies do not differentiate 
both variants. Due to the lack of available data concern-
ing the expression pattern of the Robo3 isoforms, the 
mRNA expression levels of Robo3A and Robo3B were 
determined in several tissues. Two mRNA tissue banks 
(Total RNA, 20 human Tissues, Clontech Laborities, Inc., 
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Mountain View, California, USA; total RNA, human tis-
sues, Ambion, Kaufungen, Germany) were used which 
contain samples from various tissues. After generating 
cDNA, the expression of Robo3A and 3B was analyzed 
via qRT-PCR. The results showed commonly a higher 
expression of Robo3B compared to Robo3A given as the 
ratio (Fig. 1b). In almost all mesenchymal tissues Robo3A 
expression is low and in some tissues not detectable at 
all (Table 1). The higher Robo3A level in all tissues of the 
brain is remarkable.
Robo3 expression in RASF compared with normal SF
Recently, a strong induction of Robo3 expression in 
activated RASF compared to expression in normal 
synovial cells was determined [9]. To examine the dif-
ferent expression of the two Robo3 isoforms in RA, the 
level of mRNA of Robo3A and Robo3B was determined 
in RASF in early and late passages based on the pre-
vious study. Robo3A mRNA expression was very low 
in RASF, whereas Robo3B mRNA showed enhanced 
expression in early versus late passages RASF (Fig. 2a). 
Thus, all tested RASF displayed a higher expression of 
Robo3B than Robo3A. The overall expression of the 
two Robo3 isoforms in normal SF from healthy donors 
was found to be at a similar level in RASF in late pas-
sages (data not shown). For detection of protein lev-
els of Robo3B a Robo3B-specific polyclonal antibody 
directed against the N-terminus of Robo3B was gener-
ated as commercially available antibodies did not rec-
ognize isoform-specific regions. Western blot analysis 
using this Robo3B antibody confirmed the elevated 
expression of Robo3B in RASF in early passages on 
protein level, whereas expression was reduced in later 
passages, clearly correlating with mRNA expression 
(Fig. 2b).
Robo3 expression in tumor cell lines compared 
to melanocytes
To investigate if tumor cells show different expression 
patterns of Robo3A and Robo3B tumor cells were ana-
lyzed, starting with melanoma. Here, mRNA levels of 
the two Robo3 isoforms were determined in different 
melanoma cell lines. Robo3A expression was very low, 
whereas Robo3B showed enhanced expression when 
comparing the ratio (Fig. 2c). Western blot analysis with 
the Robo3B-specific antibody also showed a stronger 
Robo3B protein expression compared to melanocytes 
(Fig. 2d). Due to the important role of Robo3 in the devel-
oping nervous system, a neuroglioma cell line (C3H4) 
was analyzed and also showed strong Robo3B expression 
(mRNA and protein). The protein expression of C3H4 is 
lower compared to the melanoma cell lines, but stronger 
in relation to primary melanocytes.
Regulation of the Robo3 isoforms through transcription 
factors
Analyses of the predicted promoter regions of Robo3A 
and Robo3B using the MatInspector Software tool (Geno-
matix Software GmbH, Munich) revealed completely 
different nucleotide sequences but interestingly similar 
clusters of transcription factor binding sites (TFBS) in 
Homo sapiens and Mus musculus (Fig.  3a). Because of 
this result, the Robo3 promoter sequences of Macaca 
mulatta were analyzed as well. Again, these revealed dif-
ferent promoter sequences of Robo3A and Robo3B but 
matching TFBS clusters (Fig.  3b). Furthermore, several 
clusters are conserved between the species. Compari-
son of the promoter regions between the species showed 
conserved and discriminating TFBS patterns for Robo3A 
(Fig.  3c) as well as for Robo3B (Fig.  3d). This involves 
for example zinc finger (ZF02), E-box binding factors 
(EBOX) and LEF1/TCF, to name a few transcription fac-
tor families. There are, however, also differentiating tran-
scription factors such as STAT5 (signal transducer and 
activator of transcription 5) and SMAD4 (Smad4 tran-
scription factor involved in TGF-beta signaling), which 
binding sequences occurred just in the predicted pro-
moter region of Robo3B.
The result of the in silico analysis indicates differ-
ent TFs, whose participation in cancer-associated path-
ways are already known and could also play a role in the 
regulation of Robo3 isoform expression. Therefore, an 
inhibitor screening was carrying out to examine poten-
tial transcription factors involved in the regulation of 
the two Robo3 isoforms. Whereas Robo3A expression 
is apparently regulated through PI3-kinase (significant 
expression differences after Ly and Wortmannin treat-
ment), Robo3B expression is regulated by a serin/threo-
nine protein kinase (significant expression differences 
after Gö6983, Bisindolylmaleimide II and Vemurafenib) 
(Fig.  4a, b). Especially when comparing the ratio of the 
expression changes of Robo3A and Robo3B after inhibi-
tor treatment (Fig.  4c), these assays suggest the distinc-
tive regulation of each Robo3 isoform.
Table 1 mRNA expression of Robo3A and Robo3B relative 
to β-actin (via qRT-PCR)
Tissue Robo3A Robo3B
Fetal liver Not detectable 1.17E−05
Lung Not detectable 1.13E−05
Liver Not detectable 3.71E−06
Salivary gland Not detectable 3.01E−06
Adrenal Not detectable 6.89E−07
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Analyses of Robo3A and Robo3B promoter activities
Based on the expression pattern of Robo3A and Robo3B 
in the melanoma cell lines, the regulation of the different 
promoters of the two isoforms was analyzed. Reporter 
gene plasmids containing either the Robo3A or the 
Robo3B promoter (−500 to −1 bp relative to translation 
start) were designed, cloned, transfected and luciferase 
activity assay were performed. The assays showed a ten-
dency for a higher promotor activity of Robo3B com-
pared to Robo3A in the tumor cell lines from melanoma 
metastasis except for Hmb2 with nearly similar activities 
of the promoter of both isoforms (Fig. 4d). The cell lines 
of primary malignant melanoma showed no significant 
differences between the activities of Robo3A and Robo3B 
a c
b d
Fig. 2 Robo expression in RASF as well as in melanoma cell lines. a mRNA levels of the two Robo3 isoforms in RASF in early and late passages 
using specific primers for both transcription variants. b Western blot analysis using the designed Robo3B-specific antibody (I.) showing the 150 kDa 
Robo3B protein (β-actin as reference, 42 kDa) and densitometric analysis normalized by β-actin (II.). c Robo3B mRNA expression relative to Robo3A 
in melanoma cell lines as well as in neuroglioma cell line (C3H4). d Protein expression of the tumor cell lines analyzed by the Robo3B-specific anti-
body (I.) and densitometric analysis normalized by β-actin (II.)
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promoter except Mel Juso with significant higher Robo3B 
promoter activity (Fig. 4e). Also in the neuroglioma cell 
lines no difference in activity of the promoters could 
be measured. These results do not explain the higher 
Robo3B expression on mRNA or protein level.
Stability assay
To determine the cause of the different expression pat-
tern of Robo3A and Robo3B other possible regulatory 
mechanisms were analyzed. In addition to the control 
of mRNA level by transcription factors, the regulation 
of mRNA turnover, is very important [15]. The treat-
ment with α-amanitin, a RNA polymerase II and III 
inhibitor, revealed a significant decrease of the Robo3A 
mRNA expression whereas the Robo3B mRNA expres-
sion is nearly stable after 24  h (Fig.  5a). Therefore, the 
cell line Mel Ei with different Robo3A and Robo3B 
mRNA expression but similar promoter activities was 
used. (For other cell lines this assay was not feasible due 
to low expression of Robo3A). The results were shown 
as raw data relating to two reference genes (β-actin and 
MIA) which clarifies that the α-amanitin treatment has 
no effect of the expression of the two reference genes that 
serve as control after 24 h (Fig. 5b).
Discussion and conclusion
In the last few decades deregulation of the Robo/Slit sys-
tem can be linked to several diseases. Especially altered 
expression in several cancer types has been described in 
recent studies [16]. However, not much is known about 
the role of the two transcriptional variants of Robo3, 
which were described already in 2005 [7]. Interestingly, 
studies revealed that variant A is incapable of ligand 
binding and therefore seems to have a different function. 
Fig. 3 Promoter analysis using MatInspector Software (Genomatix Software GmbH, Munich). a The predicted promoter regions of Robo3A and 
Robo3B revealed similar clusters of transcription factor binding sites (TFBS) in Homo sapiens and Mus musculus whereas the nucleotide sequences 
differ completely. The Robo3B promoter sequence of Macaca mulatta was analyzed analogously to the human and mouse promoter sequences 
of Robo3B and also revealed different promoter sequences of Robo3A and Robo3B but matching TFBS clusters. b Several of the TFBS clusters were 
conserved between the species. c, d Comparison of the promoter regions between the species showed conserved TFBS patterns for Robo3A (c) 
and for Robo3B (d)





Fig. 4 Regulation of the two Robo3 isoforms. a–c Mel Ei were treated with several inhibitors for 24 h. The amount of Robo3A (A) respectively 
Robo3B (B) mRNA expression was quantified by real-time (RT)-PCR and showed varied expression pattern especially when comparing the ratio of 
Robo3B relative to Robo3A (C). d, e Reporter gene assays using specific Robo3A or the Robo3B promoter plasmid. Luciferase activity was measured 
in melanoma cell lines as well as in neuroglioma cell line (C3H4). d A significantly increased promotor activity of the Robo3B promotor compared 
to the Robo3A promotor was measured in all metastasis cell lines of melanoma (Mel Im, A375, HTZ19d) except Hmb2. e No significant differences 
were found in primary tumor of melanoma except Mel Juso. Also no significant differences in the neuroglioma cell line
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However, all recent studies focusing on Robo3 ignored 
this fact including our own studies and used tools, which 
do not distinguish the variants [9, 17, 18].
Previously, our group revealed that Robo3 expression 
is altered in synovial fibroblasts of rheumatoid arthritis 
patients [9]. Currently, there are no commercially avail-
able Robo3A- or Robo3B-specific antibodies. After gen-
erating of a Robo3B-specific antibody, it was possible to 
show that Robo3B is the up-regulated isoform in RASF 
and melanoma at mRNA and protein level.
By analyzing the expression pattern of the Robo3 iso-
forms in several tissues, it was observed that Robo3B is 
the predominant isoform. Based on the fact of the high 
expression of Robo3B in mostly all mesenchymal tis-
sues it can be speculated that this isoform might play 
an increasingly crucial role in comparison to Robo3A. 
Furthermore, the enhanced Robo3B expression in 
RASF and melanoma is an indication that the upregula-
tion contribute to tumorigenesis and progression. Denk 
et al. already showed a connection between the deregu-
lation of Robo3 in RASF and the aggressiveness of the 
fibroblasts [9]. The increased Robo3 expression in early 
passages but decreased expression in later passages sug-
gests the involvement in the initial stage of RA, especial 
in the migration and invasion of SF in RA. The results of 
this new study indicate that the variant B plays the cru-
cial role for the enhanced migration potential of RASF 
and melanoma cells. In this context, the predominant 
Robo3B expression in mostly all mesenchymal tissues 
and the upregulation in diseases indicate that these cells 
apparently undergo epithelial to mesenchymal transition 
(EMT) [19]. In addition, a recent study demonstrated 
that Robo3 over-expression promotes growth, invasion 
and metastasis of pancreatic cancer cells [17]. All these 
facts advocate this hypothesis.
Interestingly, the higher Robo3A expression compared 
to Robo3B in several neuronal tissues might be an indica-
tion that Robo3A has a specific function in the brain. It 
is already known that the transmembrane receptor Robo 
functions as axon guidance molecule and that mutations 
in the Robo3 gene can lead to an autosomal recessive dis-
order [20]. The observed up-regulated Robo3B mRNA 
expression in the neuroglioma cell line also suggests that 
the deregulation of Robo3B can be connected to tumor 
a b
Fig. 5 Mel Ei were treated with the transcriptional inhibitor a-amanitin for 24 h. a mRNA expression levels of the two Robo3 isoforms determined 
via qRT-PCR show a significant decrease of the relative Robo3A expression after 24 h, whereas the relative Robo3B expression is nearly unchanged. 
b Two reference genes (MIA and β-actin) with already known differing mRNA stabilities are used. No significant variances were measured
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development of the central nervous system. Summariz-
ing the expression pattern in healthy and diseased tissue 
on mRNA and protein level, a clear cell-type dependent 
regulation of Robo3A and Robo3B was observed.
In order to understand the underlying regulation of 
expression possible signaling pathways for the control 
of gene expression were investigated. The differential 
expression of the Robo3 isoforms could to be due to the 
usage of alternative promoters. About 30–50  % of the 
human genes are under the control of alternative pro-
moters [21, 22]. In this case, the expression pattern of 
transcription factors in different cell types would be the 
reason for the distinct expression of the two isoforms. 
The gene expression control has already been described 
for the Robo1 isoforms. Here, alternative promoters and 
transcription start sites are used [23]. Nonetheless, the 
reporter gene assays performed in this study revealed 
significant differences in promoter activity only for some 
cancer cell lines. However, the results of the inhibitor 
assay suggest that the variants are regulated through dif-
ferent signaling pathways. Because not only one specific 
inhibitor showed significant expression changes it could 
be inferred that more than one specific pathway plays 
a role for the Robo3 isoforms. Particularly for Robo3B 
a serine/threonine kinase seems to be involved in the 
regulation, like already described for rheumatoid arthri-
tis and melanoma [24, 25]. More than this, the signifi-
cant expression change of Robo3B after treatment with 
Vemurafenib, a selective inhibitor of mutated BRAF, can 
be linked with malignant melanoma [26]. The inhibitor 
screening indicates a cell- and isoform-specific regula-
tion nevertheless this does not completely correlate with 
the mRNA expression levels. Therefore, the expression 
of the isoforms cannot solely be regulated by alterna-
tive promoters but also has to be modified via additional 
mechanisms.
Since the previous experiments did not reveal a com-
plete explanation, alternative regulation mechanisms on 
post-transcriptional or -translational levels, as specu-
lated for Robo proteins in growing axons, were consid-
ered [27, 28]. The mRNA turnover is a complex system 
including the process of mRNA degradation with cis-
acting and trans-acting elements [15]. In this study we 
demonstrated that the Robo3B mRNA is more stable 
than the Robo3A mRNA. Short half-lives are already 
known for many proto-oncogenes like c-fos and c-myc 
because of AU-rich elements in the 3′UTR [29, 30]. The 
most cis-acting elements are in the 3′UTR but such ele-
ments can also be found in the 5′UTR. For example, the 
interleukin-2 mRNA has a JNK response element (JRE) 
in the 5′UTR [31]. The specific binding of two RNA-
binding proteins, recognize the 5′JRE, ensures the mRNA 
stability. Possibly, the Robo3B mRNA has such elements, 
which contribute to the stabilization. Also conceivable is 
the inactivation or loss of such elements in the Robo3A 
mRNA. Whatever the crucial regulatory element might 
be it has to be located in the 5′UTR because Robo3A and 
Robo3B differ only by a few amino acids at the N-termi-
nus. In this respect, the differing 5′UTR lengths may lead 
to a remarkably divergent translational potential.
Taken together, this is the first study specifically analyz-
ing expression of the two isoforms of the repellent fac-
tor Robo3. The results endorse that Robo3A and Robo3B 
are using alternative promoters whereby the regulation is 
apparently cell- and isoform-specific. Furthermore, also 
the mRNA stability seems to be crucial for the regulation. 
Especially Robo3B, which is able to bind the ligand Slit, 
apparently plays a substantial role in diseases and might 
be therefore a novel therapeutic target. Here, differentia-
tion between both isoform is of strong importance.
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